Privacy Policy
Signals Blog

Contributors

Categories

What drives research in the field of biomaterials?

by | Apr 22, 2015

. By Hamideh Emrani It always feels amazing to find a solution to a problem or challenge. I think this huge sense of accomplishment is what drives many people in the research community. During my academic career, I have come across some remarkable scientists and...

Regenerative Medicine Deal Review: March

by | Apr 13, 2015

. Welcome to your deal review for the month of March. Cellular Dynamics threw shareholders for a loop after making a seemingly hasty decision to sell the company off to Fujifilm in a $307* million deal. Merck and synthetic biology specialist Intrexon announced a...

Update from the Clinic: March

by | Apr 7, 2015

. Welcome to your Update from the Clinic for the month of March. Investors weren’t so keen on Neuralstem’s topline results in amyotropic lateral sclerosis (ALS). NeoStem’s follow-up data from its PreSERVE study in acute myocardial infarction (AMI) was somewhat...

Update from the Clinic: February

by | Mar 25, 2015

. Welcome to your Update from the Clinic for the month of February. Northwest Biotherapeutics received approval from Health Canada to proceed with its ongoing Phase 3 clinical study in Glioblastoma multiforme at clinical sites in Quebec. Sangamo and bluebird bio both...

Cell Therapy 2.0 – warts and all

by | Mar 16, 2015

> The last 15 years of stem cell research have been full of hope and promises – some of it delivered upon, most of it not quite there yet, and some of it miserably failed. I guess that is to be expected in a highly experimental area of medicine, but one of the most...

Right Turn: Commercializing iPSCs – Infographics

by | Mar 6, 2015

. The beauty of an infographic (or two) is it speaks for itself.   Shared with permission of BioInformant: http://www.bioinformant.com/   Our regular feature, Right Turn, appears every Friday and we invite you to submit your own blog to info(at)ccrm.ca. We...